In addition, these inhibitors not only disrupt HEC1-NEK2A protein interaction but also promote NEK2A degradation through the proteasome pathway and may act as powerful cancer therapeutic for NEK2A and HEC1 overexpressing cancers. This evidence concerns the gene NDC80 and cancer.